BERWYN, Pa., July 05, 2023 (GLOBE NEWSWIRE) — Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the effectiveness of cancer treatments and quality of life for the patients that receive them, today announced that Greg Bosch,…Read More
Panavance Therapeutics to Participate in the Virtual Investor Summer Spotlight Series
